Potential of Induced Pluripotent Stem Cells (iPSCs) for Treating Age-Related Macular Degeneration (AMD)

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2016 Dec 13

PMID 27941641

Citations 15

Authors

Mark Fields

Hui Cai

Jie Gong

Lucian Del Priore

Affiliations

Soon will be listed here.

Abstract

The field of stem cell biology has rapidly evolved in the last few decades. In the area of regenerative medicine, clinical applications using stem cells hold the potential to be a powerful tool in the treatment of a wide variety of diseases, in particular, disorders of the eye. Embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are promising technologies that can potentially provide an unlimited source of cells for cell replacement therapy in the treatment of retinal degenerative disorders such as age-related macular degeneration (AMD), Stargardt disease, and other disorders. ESCs and iPSCs have been used to generate retinal pigment epithelium (RPE) cells and their functional behavior has been tested in vitro and in vivo in animal models. Additionally, iPSC-derived RPE cells provide an autologous source of cells for therapeutic use, as well as allow for novel approaches in disease modeling and drug development platforms. Clinical trials are currently testing the safety and efficacy of these cells in patients with AMD. In this review, the current status of iPSC disease modeling of AMD is discussed, as well as the challenges and potential of this technology as a viable option for cell replacement therapy in retinal degeneration.

Citing Articles

Current Landscape of iPSC Haplobanks.

Escriba R, Beksac M, Bennaceur-Griscelli A, Glover J, Koskela S, Latsoudis H Stem Cell Rev Rep. 2024; 20(8):2155-2164.

PMID: 39276260 PMC: 11554736. DOI: 10.1007/s12015-024-10783-7.

Advances in induced pluripotent stem cell-derived cardiac myocytes: technological breakthroughs, key discoveries and new applications.

Clancy C, Santana L J Physiol. 2024; 602(16):3871-3892.

PMID: 39032073 PMC: 11326976. DOI: 10.1113/JP282562.

Identification of Age-associated Proteins and Functional Alterations in Human Retinal Pigment Epithelium.

Jin X, Liu J, Wang W, Li J, Liu G, Qiu R Genomics Proteomics Bioinformatics. 2022; 20(4):633-647.

PMID: 35752290 PMC: 9880895. DOI: 10.1016/j.gpb.2022.06.001.

Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part II: Cell and Tissue Engineering Therapies.

Jemni-Damer N, Guedan-Duran A, Fuentes-Andion M, Serrano-Bengoechea N, Alfageme-Lopez N, Armada-Maresca F Front Bioeng Biotechnol. 2020; 8:588014.

PMID: 33363125 PMC: 7758210. DOI: 10.3389/fbioe.2020.588014.

Pluripotent stem cell-based gene therapy approach: human de novo synthesized chromosomes.

Sinenko S, Ponomartsev S, Tomilin A Cell Mol Life Sci. 2020; 78(4):1207-1220.

PMID: 33011821 PMC: 11072874. DOI: 10.1007/s00018-020-03653-1.

References

Gong J, Fields M, Moreira E, Bowrey H, Gooz M, Ablonczy Z . Differentiation of Human Protein-Induced Pluripotent Stem Cells toward a Retinal Pigment Epithelial Cell Fate. PLoS One. 2015; 10(11):e0143272. PMC: 4659559. DOI: 10.1371/journal.pone.0143272. View

Moreira E, Cai H, Tezel T, Fields M, Del Priore L . Reengineering Human Bruch's Membrane Increases Rod Outer Segment Phagocytosis by Human Retinal Pigment Epithelium. Transl Vis Sci Technol. 2015; 4(5):10. PMC: 4633034. DOI: 10.1167/tvst.4.5.10. View

Reardon S, Cyranoski D . Japan stem-cell trial stirs envy. Nature. 2014; 513(7518):287-8. DOI: 10.1038/513287a. View

Sugita S, Iwasaki Y, Makabe K, Kimura T, Futagami T, Suegami S . Lack of T Cell Response to iPSC-Derived Retinal Pigment Epithelial Cells from HLA Homozygous Donors. Stem Cell Reports. 2016; 7(4):619-634. PMC: 5063628. DOI: 10.1016/j.stemcr.2016.08.011. View

Li Y, Wu W, Hsu C, Nguyen H, Tsai Y, Chan L . Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther. 2014; 22(9):1688-97. PMC: 4435479. DOI: 10.1038/mt.2014.100. View

Warnke P, Alamein M, Skabo S, Stephens S, Bourke R, Heiner P . Primordium of an artificial Bruch's membrane made of nanofibers for engineering of retinal pigment epithelium cell monolayers. Acta Biomater. 2013; 9(12):9414-22. DOI: 10.1016/j.actbio.2013.07.029. View

Wang H, Yagi F, Cheewatrakoolpong N, Sugino I, Zarbin M . Short-term study of retinal pigment epithelium sheet transplants onto Bruch's membrane. Exp Eye Res. 2003; 78(1):53-65. DOI: 10.1016/j.exer.2003.09.024. View

Tezel T, Del Priore L, Kaplan H . Reengineering of aged Bruch's membrane to enhance retinal pigment epithelium repopulation. Invest Ophthalmol Vis Sci. 2004; 45(9):3337-48. DOI: 10.1167/iovs.04-0193. View

Yvon C, Ramsden C, Lane A, Powner M, da Cruz L, Coffey P . Using Stem Cells to Model Diseases of the Outer Retina. Comput Struct Biotechnol J. 2015; 13:382-9. PMC: 4477013. DOI: 10.1016/j.csbj.2015.05.001. View

10.

Buchholz D, Hikita S, Rowland T, Friedrich A, Hinman C, Johnson L . Derivation of functional retinal pigmented epithelium from induced pluripotent stem cells. Stem Cells. 2009; 27(10):2427-34. DOI: 10.1002/stem.189. View

11.

Li Y, Tsai Y, Hsu C, Erol D, Yang J, Wu W . Long-term safety and efficacy of human-induced pluripotent stem cell (iPS) grafts in a preclinical model of retinitis pigmentosa. Mol Med. 2012; 18:1312-9. PMC: 3521789. DOI: 10.2119/molmed.2012.00242. View

12.

Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S . Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature. 2013; 494(7435):100-4. DOI: 10.1038/nature11807. View

13.

Tezel T, Del Priore L . Reattachment to a substrate prevents apoptosis of human retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol. 1997; 235(1):41-7. DOI: 10.1007/BF01007836. View

14.

Nguyen H, Li Y, Tsang S . Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases. J Clin Med. 2015; 4(4):567-78. PMC: 4470156. DOI: 10.3390/jcm4040567. View

15.

Tezel T, Del Priore L . Repopulation of different layers of host human Bruch's membrane by retinal pigment epithelial cell grafts. Invest Ophthalmol Vis Sci. 1999; 40(3):767-74. View

16.

Paik D, Dillon J, Galicia E, Tilson M . The nitrite/collagen reaction: non-enzymatic nitration as a model system for age-related damage. Connect Tissue Res. 2001; 42(2):111-22. DOI: 10.3109/03008200109014253. View

17.

Cheng S, Park E, Pehar A, Rooney A, Gallicano G . Current progress of human trials using stem cell therapy as a treatment for diabetes mellitus. Am J Stem Cells. 2016; 5(3):74-86. PMC: 5107652. View

18.

Jager R, Mieler W, Miller J . Age-related macular degeneration. N Engl J Med. 2008; 358(24):2606-17. DOI: 10.1056/NEJMra0801537. View

19.

Kumar A, Narayanan K, Chaudhary R, Mishra S, Kumar S, Vinoth K . Current Perspective of Stem Cell Therapy in Neurodegenerative and Metabolic Diseases. Mol Neurobiol. 2016; 54(9):7276-7296. DOI: 10.1007/s12035-016-0217-4. View

20.

Singh R, Phillips M, Kuai D, Meyer J, Martin J, Smith M . Functional analysis of serially expanded human iPS cell-derived RPE cultures. Invest Ophthalmol Vis Sci. 2013; 54(10):6767-78. PMC: 3799561. DOI: 10.1167/iovs.13-11943. View